Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

14:50
10/06/16
10/06
14:50
10/06/16
14:50

Battleground: Alnylam plunges after revusiran pulled, but some see opportunity

Shares of Alnylam Pharmaceuticals (ALNY) crashed Thursday after the biopharmaceutical company decided to stop development of revusiran, one of its late-stage drug prospects, in the wake of several patient deaths. Wall Street was mixed on the news, with some analysts highlighting that revusiran used older technology that required extremely high doses, and others warning of increased uncertainty surrounding the company's pipeline. BACKGROUND: Alnylam announced Wednesday evening it is ending development of revusiran, a gene modifier that was in late-stage development to treat heart disease amyloidosis, after an emergency review of the Phase 3 "ENDEAVOUR" study revealed greater patient deaths in the revusiran study arm as compared to the placebo group. On a subsequent conference call, Alnylam executives emphasized that revusiran uses first-generation "GalNAc" drug delivery technology, which increases drug exposure by 12-30 times relative to the improved ESC-GalNAc technology that its other candidates use. The company did not offer an explanation for the deaths, but did note that the data review committee found no conclusive evidence of drug-related nerve damage. The company declined to give full details of the number of deaths in the study until further review, saying only that "the total number of deaths was 18 and there was an imbalance. It wasn't 18 [revusiran deaths] to zero [placebo deaths] -- it was an imbalance." PIPER SAYS BUY ON WEAKNESS: Piper Jaffray analyst Edward Tenthoff does not believe the discontinuation has any read-through to the Phase 3 study of patisiran or Alnylam's seven other RNAi gene interference therapies that use ESC-GalNAc technology. Tenthoff highlights that revusiran was the company's only first-generation GalNAc drug and that none of the 18 deaths were deemed drug-related, leading him to reiterate an Overweight rating while trimming his price target to $106 from $118, adding that he would buy the stock amid today's weakness. BARCLAYS SAYS OTHER BIOTECHS MORE ATTRACTIVE: Barclays analyst Geoff Meacham downgraded Alnylam to Equal Weight and cut his target to $50 from $85. Meacham still feels "very comfortable" with patisiran as well as the company's hemophilia program, for which he models a respective 80% and 50% success chance, but he views other comparably-sized biotech names such as Neurocrine (NBIX), Prothena (PRTA) and Incyte (INCY) as more attractive over the next year. The analyst does not have any broader concerns about the RNAi platform, and emphasizes that more than 800 patients have been safely dosed using the company's other delivery technologies. COWEN SAYS RESUVIAN ONLY MINOR DRIVER: Cowen analyst Ritu Baral reiterated an Outperform rating on Alnylam while cutting her target to $100 from $150, saying she sees no contagion to the company's remaining drug programs. The halt doesn't signal an issue with Alnylam's broader platform, she says, adding that the previous Phase 2 revusiran trials hadn't produced much hopeful data and that the drug was only a "minor driver" in her valuation model. That said, Baral suspects that the 18 death imbalance was indeed a "profound" imbalance, though she reiterates management commentary that the elderly patient population was in an advanced state of disease and taking many concomitant medications. JEFFERIES SAYS 'MAJOR SETBACK': Jefferies analyst Gena Wang kept her Buy rating on Alnylam and lowered her price target to $58 from $86. Though the impact of the drug halt is likely program/disease specific, it is still a "major setback" and Wang sees "high risk" for Alnylam's ALN-TTRsc02, which is also being evaluated in hereditary amyloidosis and uses the same RNA sequencing as revusiran. LEERINK SEES INCREASED UNCERTAINTY: Leerink analyst Michael Schmidt downgraded Alnylam to Market Perform from Outperform while cutting his target to $40 from $107. While he still believes that the company's RNAi platform holds "tremendous" potential and that other programs that use next-generation technology "are at this point not affected," Schmidt says the halt nevertheless raises uncertainty around Alnylam's pipeline. JPMORGAN SAYS ALNYLAM LOST KEY ASSET: JPMorgan analyst Anupam Rama cut Alnylam to Neutral while lowering his target to $51 from $83. Revusiran was a "key asset" for the company and a central piece of his thesis that Alnylam was being undervalued. With the company's patisiran maximally represented in his valuation model and upcoming data from the rest of its pipeline "likely being more incremental than game changing," Rama does not see meaningful near-term value creation, leading him to move to the sidelines. The analyst noted that he had forecast peak revusiran sales of nearly $2B across the U.S. and Western Europe, or roughly $18-$20 per share. PRICE ACTION: Shares of Alnylam have crashed 47% to $37.05. The Medicines Co. (MDCO), Alnylam's partner in a ALN-PCSsc program, is down 9.9% to $34.70 in late afternoon trading.

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

NBIX

Neurocrine

$51.26

0.99 (1.97%)

PRTA

Prothena

$62.92

1.11 (1.80%)

INCY

Incyte

$95.69

1.52 (1.61%)

  • 07

    Oct

  • 07

    Oct

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Ionis has no read through from negative Alnylam data, says Wells Fargo
After Ionis (IONS) competitor Alnylam Pharmaceuticals (ALNY) announced that it was terminating the development of its revusiran RNAi drug due to poor outcomes in clinical trials, Wells Fargo thinks that the news is "a significant positive" for Ionis because it eliminates a competitor. The firm says that Ionis' drug is significantly different than Alnylam's product, and it believes that Ionis' treatment appears to be superior. The firm keeps an Outperform rating on Ionis.
10/06/16
COWN
10/06/16
NO CHANGE
Target $100
COWN
Outperform
Alnylam price target lowered to $100 from $150 at Cowen
Cowen analyst Ritu Baral noted Alnylam announced the discontinuation of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy due to risk/benefit and safety signals. The analyst does not believe it signals any risk to the platform, as other programs have shown solid safety. Baral said revusiran was a minor driver so she maintained her Outperform rating and lowered her price target to $100 from $150 on Alnylam shares.
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded on reduced competition, valuation at BMO Capital
As noted earlier, BMO Capital upgraded Ionis (IONS) to Outperform from Market Perform. After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, BMO Capital analyst Do Kim expects Ionis to benefit from the reduced competition. Kim recommends buying Ionis' stock on weakness today. Target to $48 from $42.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

10/06/16
JEFF
10/06/16
NO CHANGE
Target $43
JEFF
Buy
Alnylam setback has no read-through to Medicines Co., says Jefferies
Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.
NBIX Neurocrine
$51.26

0.99 (1.97%)

06/29/16
HCWC
06/29/16
INITIATION
Target $80
HCWC
Buy
Neurocrine initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Neurocrine Biosciences with a Buy rating and $80 price target.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
10/04/16
LEER
10/04/16
INITIATION
Target $70
LEER
Outperform
Neurocrine reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Neurocrine with an Outperform rating and $70 price target.
PRTA Prothena
$62.92

1.11 (1.80%)

08/03/16
LTCO
08/03/16
NO CHANGE
Target $80
LTCO
Buy
Prothena price target raised to $80 from $77 at Ladenburg
Ladenburg Thalmann analyst Robert Hazlett said the recently released clinical data from the Phase 1/2 study of NEOD001 continue to point to promising organ responses that do not appear to be related to prior plasma cell directed therapy. Noting there are catalysts upcoming for NEOD001, PRX002 and PRX003, the analyst raised his price target on the stock to $80, adding that he assigns a 70% probability of Prothena operating independently and a 30% probability to a takeover.
09/27/16
RBCM
09/27/16
NO CHANGE
RBCM
Prothena CEO change 'neutral, natural, and positive' says RBC Capital
Afte Prothena announced its CEO was taking a medical leave and that it was elevating its COO, Gene Kinney, to interim CEO, RBC Capital analyst Michael Yee says "this a a neutral and natural positive development." Yee reports that Kinney " has been generally in charge of and overseen the R&D and clinical development of their 3 lead programs and involved in leading discussions with the FDA." The analyst believes that the company had previously been planning for succession and that investors should not be surprised by this development, as they knew that the CEO had health problems. Yee keeps an Outperform rating on the shares.
09/27/16
UBSW
09/27/16
NO CHANGE
Target $73
UBSW
Buy
Prothena management has continuity during CEO leave of absence, says UBS
UBS analyst Jeffrey Hung noted that Prothena's COO Gene Kinney will lead the company while its CEO, Dale Schenk, is on a medical leave of absence. Hung notes that the NEOD001 strategy is already largely in place and he believes the Board's confidence in Kinney, combined with his recent promotion, points to the potential for a natural succession. The analyst keeps a Buy rating and $73 price target on Prothena shares.
INCY Incyte
$95.69

1.52 (1.61%)

09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
RAJA
09/29/16
UPGRADE
Target $115
RAJA
Outperform
Incyte upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Reni Benjamin upgraded Incyte to Outperform with a $115 price target following the release of an abstract showcasing "positive" long-term follow-up results for epacadostat in melanoma. Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab, Benjamin tells investors in a research note.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

, BABA

Alibaba

$180.07

0.09 (0.05%)

07:17
09/20/17
09/20
07:17
09/20/17
07:17
Periodicals
Amazon takes on rivals in India digital payments market, The Information says »

Amazon (AMZN) has taken…

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

BABA

Alibaba

$180.07

0.09 (0.05%)

SFTBF

SoftBank

$82.75

4.45 (5.68%)

GOOG

Alphabet

$921.81

6.81 (0.74%)

GOOGL

Alphabet Class A

$936.86

7.11 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

SBNY

Signature Bank

$120.15

0.21 (0.18%)

07:16
09/20/17
09/20
07:16
09/20/17
07:16
Downgrade
Signature Bank rating change  »

Signature Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HK

Halcon Resources

$6.23

-0.19 (-2.96%)

07:14
09/20/17
09/20
07:14
09/20/17
07:14
Hot Stocks
Halcon Resources announces sale of non-operated Williston Basin assets »

Halcon Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

07:14
09/20/17
09/20
07:14
09/20/17
07:14
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$32.49

-0.03 (-0.09%)

07:12
09/20/17
09/20
07:12
09/20/17
07:12
Conference/Events
Cisco management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 22

    Oct

  • 15

    Nov

AVEO

AVEO Oncology

$3.84

0.07 (1.86%)

, BMY

Bristol-Myers

$62.93

0.23 (0.37%)

07:12
09/20/17
09/20
07:12
09/20/17
07:12
Hot Stocks
AVEO Oncology, EUSA Pharma announce TiNivo combination study opt-in »

AVEO Oncology (AVEO) and…

AVEO

AVEO Oncology

$3.84

0.07 (1.86%)

BMY

Bristol-Myers

$62.93

0.23 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 18

    Oct

  • 26

    Oct

  • 09

    Nov

  • 05

    Mar

ADBE

Adobe

$156.60

0.83 (0.53%)

07:12
09/20/17
09/20
07:12
09/20/17
07:12
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SUPN

Supernus

$38.05

-11.6 (-23.36%)

07:11
09/20/17
09/20
07:11
09/20/17
07:11
Recommendations
Supernus analyst commentary  »

Jefferies still sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

WFC

Wells Fargo

$53.36

0.65 (1.23%)

07:10
09/20/17
09/20
07:10
09/20/17
07:10
Periodicals
Wells Fargo general counsel aims to clean up reputation, Reuters reports »

Wells Fargo general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 12

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

ELY

Callaway Golf

$14.14

0.12 (0.86%)

07:09
09/20/17
09/20
07:09
09/20/17
07:09
Recommendations
Callaway Golf analyst commentary  »

Callaway Golf EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$252.46

-0.62 (-0.24%)

07:09
09/20/17
09/20
07:09
09/20/17
07:09
Recommendations
Boeing analyst commentary  »

Boeing price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

MTCH

Match Group

$23.45

-0.02 (-0.09%)

07:08
09/20/17
09/20
07:08
09/20/17
07:08
Recommendations
Match Group analyst commentary  »

Match Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:08
09/20/17
09/20
07:08
09/20/17
07:08
Hot Stocks
Breaking Hot Stocks news story on General Mills »

General Mills down 4.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

KPTI

Karyopharm

$10.52

-0.34 (-3.13%)

07:07
09/20/17
09/20
07:07
09/20/17
07:07
Hot Stocks
Karyopharm: 'successful' outcome from Phase 2 portion of Phase 2/3 SEAL study »

Karyopharm reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:05
09/20/17
09/20
07:05
09/20/17
07:05
Hot Stocks
General Mills CEO says FY18 priority is 'strengthening our topline performance' »

"Our number one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SNY

Sanofi

$49.10

0.46 (0.95%)

, ALNY

Alnylam

$75.04

-0.96 (-1.26%)

07:05
09/20/17
09/20
07:05
09/20/17
07:05
Hot Stocks
Sanofi and Alnylam report topline results of patisiran in ATTR amyloidosis »

Sanofi's (SNY)…

SNY

Sanofi

$49.10

0.46 (0.95%)

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ADBE

Adobe

$156.60

0.83 (0.53%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Recommendations
Adobe analyst commentary  »

Adobe near-term weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

WDC

Western Digital

$89.92

0.74 (0.83%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Technical Analysis
Technical View: Western Digital falls as Toshiba selects Bain-led group as buyer »

Toshiba (TOSBF, TOSYY)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:04
09/20/17
09/20
07:04
09/20/17
07:04
Hot Stocks
General Mills CEO says 'confident in improved momentum' for rest of year »

CEO Harmening said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SIX

Six Flags

$56.75

-0.32 (-0.56%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
Six Flags says no expected material impact from Mexico earthquake »

Six Flags Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

PG

Procter & Gamble

$94.17

1.02 (1.10%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
Procter & Gamble: Peltz 'lacks specific qualities' P&G seeking in board members »

The Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$55.38

-1.05 (-1.86%)

07:03
09/20/17
09/20
07:03
09/20/17
07:03
Hot Stocks
General Mills reports Q1 gross margin down 150 bps to 34.8% »

Gross margin decreased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

07:02
09/20/17
09/20
07:02
09/20/17
07:02
General news
MBA Mortgage Applications Composite Index data reported »

Week of 9/15 MBA Mortgage…

IDN

Intellicheck

07:02
09/20/17
09/20
07:02
09/20/17
07:02
Initiation
Intellicheck initiated  »

Intellicheck initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

, SNY

Sanofi

$49.10

0.46 (0.95%)

07:02
09/20/17
09/20
07:02
09/20/17
07:02
Hot Stocks
Alnylam, Sanofi say APOLLO Phase 3 study met primary, secondary endpoints »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$75.04

-0.96 (-1.26%)

SNY

Sanofi

$49.10

0.46 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.